CollPlant Regains Compliance with Nasdaq Minimum Bid Price Requirement
Why now
Thesis: Removes Nasdaq delisting overhang for small-cap biotech
Catalyst to watch: Next clinical or financing update
Main risk: Price could fall below bid threshold again
Why it matters
Regaining Nasdaq compliance removes a delisting overhang for a small-cap biotech; minimal broader impact.
Details
Nasdaq confirms the Company satisfies continued listing criteria under Listing Rule 5550(a)(2), officially closing the compliance matter Follows the recent completion of the LightSolver acquisition, marking CollPlant's strategic expansion into high-performance computing (HPC) and...
Sources
- prnewswire · 2026-09-22 11:30 UTC